These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18853984)

  • 1. Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass.
    Picardi A; Vespasiani-Gentilucci U
    Am J Gastroenterol; 2008 Dec; 103(12):3036-8. PubMed ID: 18853984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens.
    Targher G
    Diabet Med; 2007 Jan; 24(1):1-6. PubMed ID: 17227317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of non-alcoholic fatty liver disease in cardiovascular disease.
    Perseghin G
    Dig Dis; 2010; 28(1):210-3. PubMed ID: 20460913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease.
    Targher G; Bertolini L; Padovani R; Poli F; Scala L; Tessari R; Zenari L; Falezza G
    Diabet Med; 2006 Apr; 23(4):403-9. PubMed ID: 16620269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers.
    Edens MA; Kuipers F; Stolk RP
    Obes Rev; 2009 Jul; 10(4):412-9. PubMed ID: 19413701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.
    Targher G; Bertolini L; Padovani R; Rodella S; Tessari R; Zenari L; Day C; Arcaro G
    Diabetes Care; 2007 May; 30(5):1212-8. PubMed ID: 17277038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic steatosis and vascular disease.
    Santoliquido A; Di Campli C; Miele L; Gabrieli ML; Forgione A; Zocco MA; Lupascu A; Di Giorgio A; Flore R; Pola P; Gasbarrini G; Gasbarrini A; Tondi P; Grieco A
    Eur Rev Med Pharmacol Sci; 2005; 9(5):269-71. PubMed ID: 16231588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis.
    Loria P; Lonardo A; Targher G
    Clin Sci (Lond); 2008 Jul; 115(1):1-12. PubMed ID: 19016656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question.
    Loria P; Lonardo A; Bellentani S; Day CP; Marchesini G; Carulli N
    Nutr Metab Cardiovasc Dis; 2007 Nov; 17(9):684-98. PubMed ID: 17560098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.
    Fan JG
    J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-alcoholic fatty liver disease: a new challenge for cardiologists].
    Tarquini R; Lazzeri C; Boddi M; Marra F; Abbate R; Gensini GF
    G Ital Cardiol (Rome); 2010 Sep; 11(9):660-9. PubMed ID: 21348181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.
    Schindhelm RK; Diamant M; Dekker JM; Tushuizen ME; Teerlink T; Heine RJ
    Diabetes Metab Res Rev; 2006; 22(6):437-43. PubMed ID: 16832839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical aspects of non-alcoholic fatty liver disease.
    Björnsson E
    Minerva Gastroenterol Dietol; 2008 Mar; 54(1):7-18. PubMed ID: 18299664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.
    Targher G; Arcaro G
    Atherosclerosis; 2007 Apr; 191(2):235-40. PubMed ID: 16970951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients.
    Mikolasevic I; Racki S; Zaputovic L; Lukenda V; Milic S; Orlic L
    Med Hypotheses; 2014 Feb; 82(2):205-8. PubMed ID: 24365277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease and its association with cardiovascular disease.
    Lizardi-Cervera J; Aguilar-Zapata D
    Ann Hepatol; 2009; 8 Suppl 1():S40-3. PubMed ID: 19381123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study.
    Adams LA; Waters OR; Knuiman MW; Elliott RR; Olynyk JK
    Am J Gastroenterol; 2009 Apr; 104(4):861-7. PubMed ID: 19293782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
    Brzozowska MM; Ostapowicz G; Weltman MD
    J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans.
    Choi SY; Kim D; Kim HJ; Kang JH; Chung SJ; Park MJ; Kim YS; Kim CH; Choi SH; Kim W; Kim YJ; Yoon JH; Lee HS; Cho SH; Sung MW; Oh BH
    Am J Gastroenterol; 2009 Aug; 104(8):1953-60. PubMed ID: 19491838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease.
    Kantartzis K; Thamer C; Peter A; Machann J; Schick F; Schraml C; Königsrainer A; Königsrainer I; Kröber S; Niess A; Fritsche A; Häring HU; Stefan N
    Gut; 2009 Sep; 58(9):1281-8. PubMed ID: 19074179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.